Abstract: Objective To evaluate the efficacy and adverse effects of albuminbound paclitaxel as the secondline treatment for osteosarcoma with lung metastasis. Methods Nineteen osteosarcoma patients with lung metastasis failed with firstline chemotherapy were received albuminbound paclitaxel（125140mg／m² iv d₁， d₈）. Twentyone days were regarded as a cycle.The efficacy was assessed according to RECIST 1.0 standard and adverse effect was evaluated by NCI-CTC 3.0 standard. Results The efficacy of 19 patients could be evaluated. No case achieved CR， with 1 PR， 5 SD and 13 PD. The disease control rate was 31.6％， and the response rate was 5.3％. The median progression free survival was 2.2 months. The adverse effect was grade one leucopenia in two cases， and other adverse effects were not observed. Conclusion Albumin-bound paclitaxel as the secondline treatment for osteosarcoma patients with lung metastasis is effective and well-tolerated.